JP2024523424A5 - - Google Patents
Info
- Publication number
- JP2024523424A5 JP2024523424A5 JP2023578074A JP2023578074A JP2024523424A5 JP 2024523424 A5 JP2024523424 A5 JP 2024523424A5 JP 2023578074 A JP2023578074 A JP 2023578074A JP 2023578074 A JP2023578074 A JP 2023578074A JP 2024523424 A5 JP2024523424 A5 JP 2024523424A5
- Authority
- JP
- Japan
- Prior art keywords
- sirna
- sirna molecule
- sequence number
- molecule according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163212976P | 2021-06-21 | 2021-06-21 | |
| US63/212,976 | 2021-06-21 | ||
| PCT/US2022/034235 WO2022271624A1 (en) | 2021-06-21 | 2022-06-21 | Inverted chimeric sirna molecules and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523424A JP2024523424A (ja) | 2024-06-28 |
| JP2024523424A5 true JP2024523424A5 (https=) | 2025-06-09 |
Family
ID=84544739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578074A Pending JP2024523424A (ja) | 2021-06-21 | 2022-06-21 | 逆位キメラｓｉＲＮＡ分子およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240309384A1 (https=) |
| EP (1) | EP4359536A4 (https=) |
| JP (1) | JP2024523424A (https=) |
| CN (1) | CN117642507A (https=) |
| AU (1) | AU2022299035A1 (https=) |
| CA (1) | CA3221985A1 (https=) |
| WO (1) | WO2022271624A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202406049D0 (en) * | 2024-04-30 | 2024-06-12 | Francis Crick Institute Ltd | Methods and compositions for treating tumours |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7951935B2 (en) * | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
| EP1989307B1 (en) * | 2006-02-08 | 2012-08-08 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
| WO2010115202A2 (en) * | 2009-04-03 | 2010-10-07 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna |
| WO2010141511A2 (en) * | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
| US9187746B2 (en) * | 2009-09-22 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | Dual targeting siRNA agents |
| AU2013315543A1 (en) * | 2012-09-14 | 2015-04-09 | Dicerna Pharmaceuticals, Inc. | Methods and compostions for the specific inhibition of MYC by double-stranded RNA |
| US10689654B2 (en) * | 2016-10-18 | 2020-06-23 | Augusta University Research Institute, Inc. | Bivalent siRNA chimeras and methods of use thereof |
| CN108866058B (zh) * | 2018-07-12 | 2021-09-10 | 苏州吉玛基因股份有限公司 | 靶向KRAS的siRNA及其在制备胰腺癌治疗药物中的应用 |
-
2022
- 2022-06-21 CA CA3221985A patent/CA3221985A1/en active Pending
- 2022-06-21 WO PCT/US2022/034235 patent/WO2022271624A1/en not_active Ceased
- 2022-06-21 AU AU2022299035A patent/AU2022299035A1/en active Pending
- 2022-06-21 EP EP22829102.7A patent/EP4359536A4/en active Pending
- 2022-06-21 US US18/571,985 patent/US20240309384A1/en active Pending
- 2022-06-21 CN CN202280044346.4A patent/CN117642507A/zh active Pending
- 2022-06-21 JP JP2023578074A patent/JP2024523424A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101201664B1 (ko) | 신규한 형태의 간섭 ｒｎａ 분자 | |
| Chi et al. | Safety of antisense oligonucleotide and siRNA-based therapeutics | |
| US20260069625A1 (en) | Organic compositions to treat kras-related diseases | |
| CN108513588A (zh) | Kras表达的调节剂 | |
| CN115315514B (zh) | 具有核苷类似物的寡核苷酸 | |
| IL269517B1 (en) | Nucleic acids for inhibiting the expression of a target gene in a cell, their conjugates, preparations containing them, and their medical uses | |
| JPH1052264A (ja) | Ｎ‐ｒａｓ発現阻害剤およびその方法 | |
| KR102759742B1 (ko) | 막관통 세린 프로테아제 6(tmprss6) 발현을 억제하기 위한 조성물 및 방법 | |
| JP5242377B2 (ja) | 癌を治療するためのガレクチン‐１を標的とするＲＮＡｉに基づく手法の使用 | |
| Wan et al. | Oligonucleotide therapeutics in cancer | |
| JP7497061B2 (ja) | Ｒｎａ分子、キメラ型ｎａ分子、二本鎖ｒｎａ分子、および二本鎖キメラ型ｎａ分子 | |
| JP2024523424A5 (https=) | ||
| Kurreck | Antisense and RNA interference approaches to target validation in pain research | |
| CN112055598A (zh) | 用于抑制gys2表达的组合物和方法 | |
| ES2627779T5 (es) | Nuevas formas adicionales de moléculas de ARN de interferencia | |
| Nakata et al. | Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer | |
| Pérez et al. | MicroRNA interference | |
| JP2023521383A5 (https=) | ||
| FR3098712A1 (fr) | Séquences siARN ciblant l'expression des gènes JAK1 ou JAK3 humains pour une utilisation thérapeutique | |
| AU2007241369A1 (en) | Means for inhibiting the expression of CD31 | |
| KR20070062515A (ko) | 가스트린-특이적 간섭 ｒｎａ | |
| WO2025227104A1 (en) | Mrna complexes, their manufacturing, and their use for treatment | |
| JP2026068029A (ja) | 一本鎖核酸及びその用途 | |
| EP4396347A1 (en) | Chimeric complex and therapeutic uses thereof | |
| Stein et al. | Oligonucleotide Therapeutics |